Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Dr Reddy's Laboratories Ltd
Cash from Operating Activities
Dr Reddy's Laboratories Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cash from Operating Activities
₹58.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cash from Operating Activities
₹42.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cash from Operating Activities
₹127.2B
|
CAGR 3-Years
46%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Cash from Operating Activities
₹43.4B
|
CAGR 3-Years
29%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Lupin Ltd
NSE:LUPIN
|
Cash from Operating Activities
₹47.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
146%
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cash from Operating Activities
₹19.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Dr Reddy's Laboratories Ltd
Glance View
In the bustling world of pharmaceuticals, Dr. Reddy's Laboratories Ltd. stands as a testament to innovation and resilience. Founded in 1984 by Dr. K. Anji Reddy, the company embarked on a journey to provide affordable and accessible medicine. Dr. Reddy's merged scientific rigor with a clear vision to eliminate health disparities worldwide. From creating complex generics and active pharmaceutical ingredients (APIs) to providing differentiated formulations, the company has built a strong foundation in both developed markets, like the United States and Europe, as well as in emerging markets such as India, Russia, and the CIS countries. This global footprint ensures that while many pharmaceutical companies are battling regulatory challenges and pricing pressures, Dr. Reddy's stays agile and competitive. The company's revenue streams primarily derive from its diverse portfolio of generic drugs, APIs, branded formulations, biologics, and proprietary products. Each sector is a strategic puzzle piece that enhances its market presence and ensures supply chain efficiency. Dr. Reddy's invests heavily in research and development to bolster its pipeline of future medications, aiming to address unmet medical needs and introduce value-added products. By leveraging strategic alliances and forging partnerships in development and distribution, the company adeptly navigates the complex landscape of the pharmaceutical industry, ensuring sustainable growth and reaffirming its commitment to affordable healthcare globally.
See Also
What is Dr Reddy's Laboratories Ltd's Cash from Operating Activities?
Cash from Operating Activities
58.8B
INR
Based on the financial report for Dec 31, 2025, Dr Reddy's Laboratories Ltd's Cash from Operating Activities amounts to 58.8B INR.
What is Dr Reddy's Laboratories Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
14%
Over the last year, the Cash from Operating Activities growth was 73%. The average annual Cash from Operating Activities growth rates for Dr Reddy's Laboratories Ltd have been 12% over the past three years , 14% over the past five years .